



## Jenna Bruce

### Partner

Seattle

+1.206.370.8025

[jenna.bruce@klgates.com](mailto:jenna.bruce@klgates.com)

## OVERVIEW

Jenna Bruce is a partner in the Seattle office of K&L Gates and focuses her practice on intellectual property litigation with an emphasis in patent litigation across a variety of technologies, including the pharmaceutical and electrical industries. She also has extensive experience in patent litigation under the Hatch-Waxman Act and has broad experience representing brand and generic pharmaceutical companies. Jenna has represented pharmaceutical and technology clients across the country in multiple jurisdictions including Federal district courts and the International Trade Commission.

Jenna has experience in different stages of litigation, including discovery, claim construction proceedings, summary judgment motions, and trial. In addition to her litigation practice, she often evaluates third-party patents to provide opinions relating to invalidity, non-infringement, and unenforceability. Further, she also assists clients in a range of matters, including regulatory issues, patentability, and due diligence.

In addition to her patent litigation practice, Jenna has experience in other complex commercial litigation cases, including false advertising, unfair competition, and breach of contract cases. She also maintains an active pro bono practice, including assisting clients on asylum matters.

## PROFESSIONAL BACKGROUND

Prior to joining K&L Gates, Jenna was an intellectual property contract lawyer for another law firm in Seattle.

## EDUCATION

- J.D., Lewis & Clark Law School, 2013
- B.S., University of Nevada, Reno, 2010 (*with distinction, Dean's List*)

## ADMISSIONS

- Bar of Washington
- United States Patent and Trademark Office

## THOUGHT LEADERSHIP POWERED BY HUB

- 15 June 2022, New FDA Draft Guidance Aiming To Prevent Drug Shortages Will Affect Pharmaceutical Manufacturers
- 31 July 2017, The Federal Circuit Weighs in on the Doctrine of Equivalents for Chemical Inventions
- 13 July 2017, Federal Circuit Instructs the PTAB on Written Description in University Interference Proceeding
- 22 May 2017, The Federal Circuit Affirms the Patent Trial and Appeal Board's Invalidation of All Claims of a Gilenya® Patent
- 28 April 2017, *Sandoz v. Amgen*—Biosimilars at the Supreme Court—Oral Argument

## NEWS & EVENTS

- 2 January 2024, K&L Gates Names Nearly 30 Partners, Government Affairs Advisors Across Firm
- 18 August 2022, More Than 350 K&L Gates Lawyers Named Among 2023 Best Lawyers in America, Ones to Watch
- 19 August 2021, Nearly 300 K&L Gates Lawyers Named Among 2022 Best Lawyers in America, Ones to Watch

## AREAS OF FOCUS

- IP Litigation
- Pharma and BioPharma Litigation